Clinical Trial Update: Effect of Ranitidine on Hyper-IgE Recurrent Infection (Job's) Syndrome [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating ranitidine for JOB's syndrome (Hyper-IgE recurrent infection syndrome) was terminated; results were posted in 2013.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyper-ige Syndrome
• Immunodeficiency
• Job Syndrome

Drugs mentioned

• Ranitidine (Ranitidine)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: JOB's Syndrome, Hyper-IgE Recurrent Infection Syndrome | Phase 2 | Status: TERMINATED | Results posted: 2013-02-04